Adial Pharmaceuticals (ADIL) Q1 2025 earnings summary

Executive summary

• Advanced AD04 for alcohol use disorder (AUD) in genetically targeted subgroups, with preparations for Phase 3 trials in the US and Europe/UK and key regulatory milestones achieved.

• Completed pharmacokinetics bridging study confirming favorable bioavailability for AD04, supporting flexible dosing.

• Received FDA support for clinical endpoints, surrogate markers, and 505(b)(2) in vitro bridging strategy, streamlining the regulatory pathway.

• Strengthened intellectual property with new patents for AD04's precision medicine approach and genetically guided use.

• No products approved or significant revenue generated to date; operations funded primarily through equity and warrant transactions.

Financial highlights

• Net loss for Q1 2025 was $2.2 million, compared to $6.5 million in Q1 2024, mainly due to absence of prior year’s non-cash inducement expense.

• Research and development expenses increased 65% year-over-year to $747,000, driven by clinical supply and consulting costs.

• General and administrative expenses rose 9% year-over-year to $1.52 million, mainly due to higher compensation and consulting.

• Cash and cash equivalents at March 31, 2025 were $2.4 million; as of May 2025, $3.9 million after warrant proceeds.

• Accumulated deficit reached $84.2 million as of March 31, 2025.

Outlook and guidance

• Current cash, including recent warrant proceeds, is expected to fund operations into Q4 2025; additional capital will be required to continue development.

• Two additional Phase 3 trials for AD04 are planned, each expected to require $8–12 million in direct expenses.

• Commercialization of AD04 is not expected before 2027.

• Preparing for End of Phase 2 FDA meeting in July to finalize Phase 3 trial design.